Related Experiment Video
Updated: Aug 11, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
[Genetic engineering approaches to the study of insulin-dependent diabetes mellitus markers]
In the present study, gene-engineering producers for proinsulin and peptide fragments of glutamic acid decarboxylase (GAD), the main autoantigens of islet cells responsible for development of insulin-dependent diabetes mellitus (IDDM), were prepared. Basing on the obtained antigens. ELISA was developed to determine the autoantibodies in sera of patients. Sera from the following two groups of IDDM patients were studied: 1) adult patients with recently developed IDDM before insulinotherapy, and 2) adult patients with long-lasting IDDM with associated complications. Insulin/proinsulin antibodies were detected in 20% patients of group 1 and 41.7% patients of group 2. In sera from IDDM patients, antibodies to two GAD fragments containing amino acid sequences 1-80 and 151-585 were also detected. 16% of sera from patients with recently developed IDDM and 37.5% of sera from patients with long-lasting IDDM reacted with N-terminal GAD fragment. 12% of sera from group 1 and 45.8% of sera from group 2 reacted with central-C-terminal GAD fragment. The rate of sera of IDDM patients with detected antibodies in this study was some lower than that described in the literature.
In the present study, gene-engineering producers for proinsulin and peptide fragments of glutamic acid decarboxylase (GAD), the main autoantigens of islet cells responsible for development of insulin-dependent diabetes mellitus (IDDM), were prepared. Basing on the obtained antigens. ELISA was developed to determine the autoantibodies in sera of patients. Sera from the following two groups of IDDM patients were studied: 1) adult patients with recently developed IDDM before insulinotherapy, and 2) adult patients with long-lasting IDDM with associated complications. Insulin/proinsulin antibodies were detected in 20% patients of group 1 and 41.7% patients of group 2. In sera from IDDM patients, antibodies to two GAD fragments containing amino acid sequences 1-80 and 151-585 were also detected. 16% of sera from patients with recently developed IDDM and 37.5% of sera from patients with long-lasting IDDM reacted with N-terminal GAD fragment. 12% of sera from group 1 and 45.8% of sera from group 2 reacted with central-C-terminal GAD fragment. The rate of sera of IDDM patients with detected antibodies in this study was some lower than that described in the literature.
Related Concept Videos
What is Genetic Engineering?
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Pharmacogenomics: Identification of New Drug Targets
Insulin: The Receptor and Signaling Pathways
Insulin: Biosynthesis, Chemistry, and Preparation
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Type II Diabetes I: Introduction

